Dulaglutide for teens with T2DM and obesity reduces HbA1c: trial
In contrast to its use in adults, however, the agent did not budge high BMI, the investigators report
Dulaglutide therapy for poorly controlled type 2 diabetes in children and youths leads to superior glycaemic control than placebo without compromising safety, research shows.
Almost three times as many patients given the GLP-1 receptor agonist achieved a HbA1c of less than 7% at 26 weeks compared with those in the placebo group, according to results from the multi-country trial.
